135 related articles for article (PubMed ID: 35953154)
1. Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology.
Leow JWH; Tang LWT; Chan ECY
Adv Pharmacol; 2022; 95():131-176. PubMed ID: 35953154
[TBL] [Abstract][Full Text] [Related]
2. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition.
Leow JWH; Chan ECY
Biochem Pharmacol; 2019 Nov; 169():113615. PubMed ID: 31445022
[TBL] [Abstract][Full Text] [Related]
3. Atypical cytochrome p450 kinetics: implications for drug discovery.
Tracy TS
Drugs R D; 2006; 7(6):349-63. PubMed ID: 17073518
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS
Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735
[TBL] [Abstract][Full Text] [Related]
5. [Research progress of the atypical kinetic profiles of cytochrome P450 enzymes].
Zeng CW; He F; Xia CH; Xiong YQ
Yao Xue Xue Bao; 2012 Jun; 47(6):725-9. PubMed ID: 22919718
[TBL] [Abstract][Full Text] [Related]
6. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Shen L; Fitzloff JF; Cook CS
Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
[TBL] [Abstract][Full Text] [Related]
7. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
8. Enzyme Kinetics of Oxidative Metabolism-Cytochromes P450.
Korzekwa K
Methods Mol Biol; 2021; 2342():237-256. PubMed ID: 34272697
[TBL] [Abstract][Full Text] [Related]
9. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
10. Enzyme kinetics of cytochrome P450-mediated reactions.
Shou M; Lin Y; Lu P; Tang C; Mei Q; Cui D; Tang W; Ngui JS; Lin CC; Singh R; Wong BK; Yergey JA; Lin JH; Pearson PG; Baillie TA; Rodrigues AD; Rushmore TH
Curr Drug Metab; 2001 Mar; 2(1):17-36. PubMed ID: 11465149
[TBL] [Abstract][Full Text] [Related]
11. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.
Lin Y; Lu P; Tang C; Mei Q; Sandig G; Rodrigues AD; Rushmore TH; Shou M
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):368-74. PubMed ID: 11259318
[TBL] [Abstract][Full Text] [Related]
12. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives.
Shou M; Mei Q; Ettore MW; Dai R; Baillie TA; Rushmore TH
Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):845-53. PubMed ID: 10359672
[TBL] [Abstract][Full Text] [Related]
13. Enzyme kinetics of oxidative metabolism: cytochromes P450.
Korzekwa K
Methods Mol Biol; 2014; 1113():149-66. PubMed ID: 24523112
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
15. Deoxyschizandrin, a naturally occurring lignan, is a specific probe substrate of human cytochrome P450 3A.
Wu J; Cao Y; Zhang Y; Liu Y; Hong JY; Zhu L; Ge G; Yang L
Drug Metab Dispos; 2014 Jan; 42(1):94-104. PubMed ID: 24131672
[TBL] [Abstract][Full Text] [Related]
16. Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.
Fowler S; Guerini E; Qiu N; Cleary Y; Parrott N; Greig G; Mallalieu NL
J Pharmacol Exp Ther; 2017 Jan; 360(1):164-173. PubMed ID: 27821711
[TBL] [Abstract][Full Text] [Related]
17. Heterotropic cooperativity in oxidation mediated by cytochrome p450.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2008 Jun; 9(5):453-62. PubMed ID: 18537580
[TBL] [Abstract][Full Text] [Related]
18. Modelling atypical CYP3A4 kinetics: principles and pragmatism.
Houston JB; Galetin A
Arch Biochem Biophys; 2005 Jan; 433(2):351-60. PubMed ID: 15581591
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
Pearce RE; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 2001 Dec; 29(12):1548-54. PubMed ID: 11717173
[TBL] [Abstract][Full Text] [Related]
20. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
